MVCD2
MCID: MCR112
MIFTS: 41

Microvascular Complications of Diabetes 2 (MVCD2)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 2

MalaCards integrated aliases for Microvascular Complications of Diabetes 2:

Name: Microvascular Complications of Diabetes 2 56 73 29 13 6 39
Proliferative Diabetic Retinopathy 73 71
Diabetic Nephropathy 73 71
Mvcd2 56 73
Microvascular Complications of Diabetes, Susceptibility to, 2 56
Proliferative Retinopathy, Diabetic, Susceptibility to 56
End-Stage Renal Disease, Diabetic, Susceptibility to 56
Proliferative Retinopathy, Diabetic 56
End-Stage Renal Disease, Diabetic 56
Diabetic End-Stage Renal Disease 73

Classifications:



External Ids:

OMIM 56 612623
OMIM Phenotypic Series 56 PS603933
MeSH 43 D048909
UMLS 71 C0011881 C0154830

Summaries for Microvascular Complications of Diabetes 2

UniProtKB/Swiss-Prot : 73 Microvascular complications of diabetes 2: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 2, also known as proliferative diabetic retinopathy, is related to microvascular complications of diabetes 3 and background diabetic retinopathy. An important gene associated with Microvascular Complications of Diabetes 2 is EPO (Erythropoietin). The drugs Methylcobalamin and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and kidney.

More information from OMIM: 612623 PS603933

Related Diseases for Microvascular Complications of Diabetes 2

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 497)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 3 12.3
2 background diabetic retinopathy 12.1
3 vitreoretinopathy, neovascular inflammatory 11.9
4 severe nonproliferative diabetic retinopathy 11.9
5 microvascular complications of diabetes 7 11.8
6 microvascular complications of diabetes 1 11.7
7 retinal detachment 11.1
8 macular retinal edema 10.9
9 renal fibrosis 10.9
10 macular holes 10.9
11 neovascular glaucoma 10.8
12 yemenite deaf-blind hypopigmentation syndrome 10.8
13 diabetic macular edema 10.8
14 vitreoretinopathy 10.7
15 glomerulonephritis 10.7
16 hydrops, lactic acidosis, and sideroblastic anemia 10.7
17 nephrotic syndrome 10.6
18 rubeosis iridis 10.6
19 retinal ischemia 10.6
20 eye disease 10.6
21 cataract 10.6
22 end stage renal failure 10.5
23 retinal disease 10.5
24 uremia 10.5
25 hypertension, essential 10.5
26 intraocular pressure quantitative trait locus 10.5
27 hyperglycemia 10.5
28 iga glomerulonephritis 10.5
29 vitreous detachment 10.5
30 membranous nephropathy 10.4
31 endophthalmitis 10.4
32 uveitis 10.4
33 neuroretinitis 10.4
34 retinal vascular disease 10.4
35 retinitis 10.4
36 glomerular disease 10.4
37 kidney hypertrophy 10.4
38 preretinal fibrosis 10.4
39 hyperinsulinism 10.4
40 atherosclerosis susceptibility 10.3
41 nephrosclerosis 10.3
42 hyperuricemia 10.3
43 cytokine deficiency 10.3
44 diabetes mellitus, noninsulin-dependent 10.3
45 retinitis pigmentosa 10.3
46 insulin-like growth factor i 10.3
47 retinoschisis 1, x-linked, juvenile 10.3
48 48,xyyy 10.3
49 rapidly involuting congenital hemangioma 10.3
50 proteasome-associated autoinflammatory syndrome 1 10.3

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 2:



Diseases related to Microvascular Complications of Diabetes 2

Symptoms & Phenotypes for Microvascular Complications of Diabetes 2

Clinical features from OMIM:

612623

Drugs & Therapeutics for Microvascular Complications of Diabetes 2

Drugs for Microvascular Complications of Diabetes 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 418)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
4
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
5
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
6
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
7
Atenolol Approved Phase 4 29122-68-7 2249
8
Methyldopa Approved Phase 4 555-30-6 38853
9
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
10
Clonidine Approved Phase 4 4205-90-7 2803
11
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
12
Capsaicin Approved Phase 4 404-86-4 1548943
13
Bevacizumab Approved, Investigational Phase 4 216974-75-3
14
Dipivefrin Approved Phase 4 52365-63-6 3105
15
Ranibizumab Approved Phase 4 347396-82-1 459903
16
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
17
Zinc Approved, Investigational Phase 4 7440-66-6 32051
18
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
19
Povidone-iodine Approved Phase 4 25655-41-8
20
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
21
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
22
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
23
Probucol Approved, Investigational Phase 4 23288-49-5 4912
24
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
25
Ramipril Approved Phase 4 87333-19-5 5362129
26
Doxazosin Approved Phase 4 74191-85-8 3157
27
Indapamide Approved Phase 4 26807-65-8 3702
28
Atorvastatin Approved Phase 4 134523-00-5 60823
29
Trandolapril Approved Phase 4 87679-37-6 5484727
30
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
31
Nisoldipine Approved Phase 4 63675-72-9 4499
32
Insulin glargine Approved Phase 4 160337-95-1
33
Insulin glulisine Approved Phase 4 207748-29-6
34
Liraglutide Approved Phase 4 204656-20-2 44147092
35
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
36
Nitric Oxide Approved Phase 4 10102-43-9 145068
37
Allopurinol Approved Phase 4 315-30-0 2094
38
Insulin lispro Approved Phase 4 133107-64-9
39
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
40
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
41
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
42
Glimepiride Approved Phase 4 93479-97-1 3476
43
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
44
Febuxostat Approved Phase 4 144060-53-7 134018
45
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
46
Canagliflozin Approved Phase 4 842133-18-0
47
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
48
Amlodipine Approved Phase 4 88150-42-9 2162
49
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
50
Glipizide Approved, Investigational Phase 4 29094-61-9 3478

Interventional clinical trials:

(show top 50) (show all 605)
# Name Status NCT ID Phase Drugs
1 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
2 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
3 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
4 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
5 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
6 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
7 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
8 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
9 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
10 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
11 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
12 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
13 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
14 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
15 A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
16 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
17 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
18 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
19 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
20 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
21 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
22 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Unknown status NCT02690883 Phase 4 Exenatide;Lispro
23 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
24 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
25 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
26 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
27 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
28 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
29 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
30 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
31 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
32 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
33 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
34 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
35 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
36 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
37 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
38 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
39 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
40 Effect of Adjunctive Intravitreal Bevacizumab Before Panretinal Photocoagulation in Macular Thickness and Retinal Nerve Fiber Layer Thickness Completed NCT01504724 Phase 4 bevacizumab
41 Ranibizumab and Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema Completed NCT04089605 Phase 4 dexamethasone implant;Ranibizumab
42 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
43 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
44 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
45 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
46 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
47 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
48 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
49 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
50 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril

Search NIH Clinical Center for Microvascular Complications of Diabetes 2

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 2

Genetic tests related to Microvascular Complications of Diabetes 2:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 2 29 EPO

Anatomical Context for Microvascular Complications of Diabetes 2

MalaCards organs/tissues related to Microvascular Complications of Diabetes 2:

40
Endothelial, Eye, Kidney, Retina, Heart, Liver, Monocytes

Publications for Microvascular Complications of Diabetes 2

Articles related to Microvascular Complications of Diabetes 2:

(show top 50) (show all 3943)
# Title Authors PMID Year
1
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. 61 56 6
18458324 2008
2
Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. 61 56
16120858 2005
3
Objective Evaluation of Proliferative Diabetic Retinopathy Using OCT. 61
31708488 2020
4
Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up. 61
31647931 2020
5
[Retinal laser treatment-avoiding mistakes]. 61
32002621 2020
6
Galectin-1 studies in proliferative diabetic retinopathy. 61
31318490 2020
7
The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study. 61
32013913 2020
8
The effects of hyperbaric oxygen therapy on diabetic retinopathy: A preliminary study. 61
31831276 2020
9
Spectrum of eye disorders in diabetes (SPEED) in India. Report # 2. Diabetic retinopathy and risk factors for sight threatening diabetic retinopathy in people with type 2 diabetes in India. 61
31937724 2020
10
Evaluation of Retinal Detachment After Diabetic Vitrectomy: Causes and Ways of Management. 61
32021068 2020
11
Intraoperative optical coherence tomography and proportional reflux hydrodissection-guided pars plana vitrectomy for complex severe proliferative diabetic retinopathy. 61
31856503 2020
12
Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy. 61
32005066 2020
13
Bariatric surgery might aggravate proliferative diabetic retinopathy. 61
31912621 2020
14
Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. 61
32001821 2020
15
Clinical and angiographic characterization of choroidal neovascularization in diabetic retinopathy. 61
31984769 2020
16
Mining the proliferative diabetic retinopathy-associated genes and pathways by integrated bioinformatic analysis. 61
31953631 2020
17
Incidence and Risk for Developing Proliferative Diabetic Retinopathy after Photocoagulation for Diabetic Maculopathy. 61
31920110 2020
18
Surgical outcomes of vitrectomy surgery for proliferative diabetic retinopathy in patients with abnormal renal function. 61
31758258 2020
19
Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation. 61
30539668 2020
20
Assessment of neuron-specific enolase, S100B and malondialdehyde levels in serum and vitreous of patients with proliferative diabetic retinopathy. 61
31571092 2020
21
Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. 61
31999300 2020
22
Retinal Non-Perfusion in Proliferative Diabetic Retinopathy Before and After Panretinal Photocoagulation Assessed by Wide Field OCT Angiography. 61
32006481 2020
23
Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage. 61
31956432 2020
24
Advanced glycation end products induce immature angiogenesis in in vivo and ex vivo mouse models. 61
31922896 2020
25
Comparison between Findings in Optical Coherence Tomography Angiography and in Fluorescein Angiography in Patients with Diabetic Retinopathy. 61
31137028 2020
26
Hydrogen sulfide serves as a biomarker in the anterior segment of patients with diabetic retinopathy. 61
31894458 2020
27
Relationship Between Aqueous Humor Levels of Cytokines and Axial Length in Patients With Diabetic Retinopathy. 61
31985528 2020
28
RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY. 61
31917731 2020
29
MiR-203a-3p inhibits retinal angiogenesis and alleviates proliferative diabetic retinopathy in oxygen-induced retinopathy (OIR) rat model via targeting VEGFA and HIF-1α. 61
31408201 2020
30
Survival Time of Visual Gains after Diabetic Vitrectomy and Its Relationship with Ischemic Heart Disease. 61
31906417 2020
31
Do Genomic Factors Play a Role in Diabetic Retinopathy? 61
31947513 2020
32
Pupillary light responses in type 1 and type 2 diabetics with and without retinopathy. 61
31943805 2020
33
Novel biomarker of sphericity and cylindricity indices in volume-rendering optical coherence tomography angiography in normal and diabetic eyes: a preliminary study. 61
31907642 2020
34
Inflammation, angiogenesis and coagulation interplay in a variety of retinal diseases. 61
31833198 2019
35
Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial. 61
30705040 2019
36
Retinal re-detachments after removal of silicone oil: Frequency and timings in a retrospective clinical study. 61
31853111 2019
37
Increased expression of periostin and tenascin-C in eyes with neovascular glaucoma secondary to PDR. 61
31863397 2019
38
RKIP negatively regulates the glucose induced angiogenesis and endothelial-mesenchymal transition in retinal endothelial cells. 61
31655041 2019
39
Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy. 61
31802372 2019
40
Intravitreal ranibizumab versus vitrectomy for recurrent vitreous haemorrhage after pars plana vitrectomy for proliferative diabetic retinopathy: a prospective study. 61
31788713 2019
41
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. 61
31542339 2019
42
Identification of Diagnostic and Prognostic microRNAs for Recurrent Vitreous Hemorrhage in Patients with Proliferative Diabetic Retinopathy. 61
31847440 2019
43
Intravitreal anti-VEGF agents and cardiovascular risk. 61
31848994 2019
44
The Inhibitory Effects of Gold Nanoparticles on VEGF-A-Induced Cell Migration in Choroid-Retina Endothelial Cells. 61
31877924 2019
45
Proliferative diabetic retinopathy as onset of type 1 diabetes. 61
31866090 2019
46
Analysis of quantitative correlations between microaneurysm, ischaemic index and new vessels in ultrawide-field fluorescein angiography images using automated software. 61
30872285 2019
47
Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy - the PRIDE study. 61
31808278 2019
48
Upregulated CD200 in pre-retinal proliferative fibrovascular membranes of proliferative diabetic retinopathy patients and its correlation with vascular endothelial growth factor. 61
31612255 2019
49
Factors Predicting Treatment Response in Anti-Vascular Endothelial Growth Factor Naïve Diabetic Macular Edema Patients Treated with Intravitreal Bevacizumab. 61
31603371 2019
50
Spectral domain optical coherence tomography based imaging biomarkers for diabetic retinopathy. 61
31571130 2019

Variations for Microvascular Complications of Diabetes 2

ClinVar genetic disease variations for Microvascular Complications of Diabetes 2:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EPO NM_000799.3(EPO):c.-1306C>ASNV risk factor 16602 rs1617640 7:100317298-100317298 7:100719675-100719675

Expression for Microvascular Complications of Diabetes 2

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 2.

Pathways for Microvascular Complications of Diabetes 2

GO Terms for Microvascular Complications of Diabetes 2

Sources for Microvascular Complications of Diabetes 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....